SCHEMBL4074808

SCHEMBL4074808

CC(C)[SiH](c1ccc(CCCOC2CCCCO2)cc1)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4C Q9H3R0 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
CHEK1 O14757 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
OPRM1 P35372 3/20 0.36
P2RX3 P56373 8/20 0.35
OPRK1 P41145 2/20 0.34
OPRD1 P41143 1/20 0.34
MGLL Q99685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073878 0.93 KDM4C (0.44) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL4079662 0.86 MEN1 (0.42) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL4072891 0.85 MEN1 (0.38) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL4072226 0.80 MEN1 (0.42) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL8844164 0.79 MEN1 (0.51) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL1002925 0.79 MEN1 (0.48) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL4074507 0.79 MEN1 (0.48) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL4074508 0.79 MEN1 (0.48) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL13953674 0.79 MEN1 (0.48) MEN1KMT2AKDM4CNPC1RAB9A
SCHEMBL27334860 0.79 MEN1 (0.48) MEN1KMT2AKDM4CNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074135-A2 SILICON DERIVATIVES FOR PET IMAGING Bayer Schering Pharma AG (DE) 2009-07-01 EP disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
EP-1970064-A1 Silicon-derivatives for pet-imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-17 EP disclosed
EP-1970064-A1 Silicon-derivatives for pet-imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-17 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035215-A1 RADIOFLUORINATION AFF2, AFF1, NUTF2 MEN1 20/4885KMT2A 2045/4885KDM4C 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.